Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958243 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA
A Phase 2 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 2
- Development phase
- 473
- Enrollment target
NCT00958243 is a Phase 2 study that has completed, run by Seqirus. The registered enrollment target is 473 participants.
The verdict
NCT00958243, a Phase 2 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 473 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immunogenicity and safety profile of CSL425 (CSL's 2009 H1N1 influenza vaccine) in a healthy pediatric population.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CSL's 2009 H1N1 Influenza Vaccine (CSL425)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 473 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00958243
The ClinicalTrials.gov registry entry for NCT00958243 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 473 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00958243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00958243 about?
NCT00958243 is a clinical study titled "A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA". The purpose of this study is to evaluate the immunogenicity and safety profile of CSL425 (CSL's 2009 H1N1 influenza vaccine) in a healthy pediatric population.
What is the current status of trial NCT00958243?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 473 participants. The study started on 2009-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00958243?
The interventions under investigation include: Placebo (BIOLOGICAL), CSL's 2009 H1N1 Influenza Vaccine (CSL425) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00958243?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.